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Abstract
Activation of the minute virus of mice (MVM) P4 promoter is a key step in the life cycle of the virus and is completely dependent on
host transcription factors. Since transcription-factor composition varies widely in different cell types, there is the possibility that only some
cell types in the host organism have the capacity to initiate expression from the P4 promoter and therefore that the promoter may be a factor
in determining the tropism of MVM. In this study, the ability of various cell types to activate P4, independent of the other virus–host
interactions, was examined in transgenic mouse lines bearing a -galactosidase reporter sequence driven by the P4 promoter. It was found
that lacZ was expressed during embryogenesis and in the adult in a cell-type-specific and differentiation-dependent pattern. The data are
consistent with cell-type and stage-specific activation of the P4 promoter having a role in determining the host cell-type range of MVM.
The ability of some parvoviruses to replicate in, and kill oncogenically transformed cells, and to destroy induced tumors in laboratory
animals is the basis of recent approaches to use MVM-based vectors in cancer gene therapy. Since these vectors rely on the activation of
the P4 promoter by the target tissues, understanding the promoter dependence on cell-type and differentiation status is important for their
design and potential use.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Minute virus of mice (MVM), a natural murine patho-
gen, is a small icosahedral virus that contains a single-
stranded, linear DNA genome, 5.1 kilobases (kb) in
length. The entire coding content of MVM, clustered in
its viral (minus) strand, is organized in two partially
overlapping transcription units having promoters at map
units 4 (P4) and 38 (P38) (Astell et al., 1986; Pintel et al.,
1983; Sahli et al., 1985). Messenger RNAs generated
from P4 encode the viral regulatory proteins NS1 and
NS2 (Cotmore and Tattersall, 1986b). Messenger RNAs
generated from the P38 promoter encode the viral capsid
proteins VP1 and Vp2 (Labieniec-Pintel and Pintel,
1986). NS1, the major regulatory protein, is a multifunc-
tional phosphoprotein (Cotmore and Tattersall, 1986a). It
plays a key role in productive infection through its var-
ious biochemical functions, including site-specific endo-
nuclease, ATPase, and helicase activities (Cotmore and
Tattersall, 1995; Jindal et al., 1994; Nuesch et al., 1995),
viral genome amplification, and trans-regulation of tran-
scription from both P4 and P38 viral promoters (Doerig
et al., 1988, 1990; Legendre and Rommelaere, 1994;
Lorson et al., 1996). The P4 promoter is regulated by
NS1 in a dose-dependent fashion (Hanson and Rhode,
1991). NS2, of which three isoforms are made as a result
of alternative splicing, is required for infection and cap-
sid assembly in cultured murine cells (Cater and Pintel,
1992; Cotmore et al., 1997) and for the pathogenicity of
the virus in vivo (Brownstein et al., 1992). The accumu-
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lating data suggest that, during MVM infection, NS2 acts
as a modulator of NS1 activity in a cell-type-specific
manner (Brandenburger et al., 1990; Legrand et al.,
1993).
Because of its limited coding capacity, the replication
of MVM (similar to that of all other autonomous parvo-
viruses) relies heavily on cellular factors, some of which
have been identified. In tissue culture, MVM replication
depends on cellular functions expressed transiently dur-
ing S-phase (Deleu et al., 1999; Tattersall, 1972) and
production of a transcriptionally active double-stranded
viral genome occurs only in mitotically active cells. Pro-
ductive infection also depends on the differentiation state
of the host cell. The early embryo and embryonic stem
cells are resistant to viral replication, but differentiated
derivatives may be sensitive (Gardiner and Tattersall,
1988; Guetta et al., 1986; Miller et al., 1977; Spalholz
and Tattersall, 1983). Cell type has also been shown to be
a determining factor in restriction of infectivity. The best
studied example of this is the allotropism displayed by
the fibrotropic (p) and lymphotropic (i) strains of MVM,
which can establish productive infections in mouse fibro-
blast and T-lymphocyte cell lines, respectively, but not in
each other’s permissive host (Spalholz and Tattersall,
1983; Tattersall and Bratton, 1983). In this case, the
different tropisms are due to a few amino acid variations
in the viral capsid protein VP2 (Gardiner and Tattersall,
1988; Maxwell et al., 1995). The regulatory NS proteins
have also been implicated in host-range determination
(Rubio et al., 2001).
Activation of the regulatory P4 promoter is a critical
step in the MVM viral life cycle. Although the activity of
P4 is later modulated by its own gene products, initial
activation is completely dependent on host cell factors.
The P4 promoter contains multiple transcription factor-
binding sites (Faisst et al., 1994), including E2F (Deleu
et al., 1999), NF-Y (Gu et al., 1995), SP1 (Pitluk and
Ward, 1991), and CRE (Perros et al., 1995, 1999). It has
also been shown to interact with a heterogeneous nuclear
ribonucleoprotein-like protein designated NSAP1 (Harris
et al., 1999). Some cell lines exhibit increased P4 pro-
moter activity in S-phase (Deleu et al., 1998), which is
important for productive infection (Deleu et al., 1999).
The P4 promoter is regulated by NS1 in a dose-dependent
fashion (Hanson and Rhode, 1991). To date, no transcrip-
tion factor has been shown to interact with the P4 pro-
moter in a developmentally dependent fashion, but the
central role of NS1 in the MVM life cycle and the
dependence of MVM on host differentiation state sug-
gested the possibility that P4 could be developmentally
regulated. Indeed, the demonstration that the Ets factor-
binding site (EBS) was required for full P4 activity in
ras-transformed rat fibroblasts cell line but did not play a
significant role in their parental, untransformed cells
(Fuks et al., 1996; Spegelaere et al., 1991) and the ob-
servation that deletions of upstream P4 promoter ele-
ments had cell-type-specific effects on the promoter ac-
tivity (Spegelaere et al., 1994) both lend support to the
hypothesis.
Potential cell-type and differentiation state-specific acti-
vation of the P4 promoter is particularly relevant in view of
the ability of MVMp and other autonomous parvoviruses to
destroy induced tumors in laboratory animals (Faisst et al.,
1998; Guetta et al., 1986) and to preferentially replicate in,
and kill, oncogenically transformed cells in vitro but not
their untransformed parental cells (Cornelis et al., 1988;
Guetta et al., 1990; Mousset et al., 1986; Salome et al.,
1990; reviewed in Rommelaere and Cornelis, 1991). Inter-
actions between the transcription products from the P4 pro-
moter, the NS1 proteins, and the host cell are believed to
account for the antineoplastic activity of some parvoviruses
(Rommelaere and Cornelis, 1991; Vanacker and Rom-
melaere, 1995). Experimental systems using this antineo-
plastic activity for the design of therapeutic vectors have
relied upon the activity of the native P4 promoter (reviewed
in Palmer and Tattersall, 2000).
In the current study, transgenic mouse lines were gen-
erated bearing a lacZ reporter gene under the regulation
of the MVM P4 promoter. This permitted the character-
ization of the activation of the P4 promoter in the context
of its normal range of potential host cells and indepen-
dent of other viral components. The tissue and cell-type
and differentiation-state dependence of activation of the
transgenic P4 promoter reported here are consistent with
the hypothesis that activation of the P4 promoter by the
host cell is partially responsible for determination of the
MVM host cell-type range.
Results
Establishing P4-LacZ transgenic mouse lines
Three of the 28 offspring from injected eggs were iden-
tified as transgenic by dot blot and Southern blot analyses.
These progenitors were used to generate the independent
transgenic lines p4:LacZ-10, p4:LacZ-11, and p4:LacZ-17;
each of those showed Mendelian inheritance of the trans-
gene. Southern blot analysis indicated that the transgenic
lines carried one to three copies of MVMP4-lacZ, each at a
different chromosomal location. The activity of the P4 pro-
moter was initially assessed by X-gal staining in embryos at
9.5, 11.5, 12.5, 13.5, and 14.5 days postcoitum (dpc) col-
lected from Tg  wt crosses. The staining was observed
from 11.5 dpc on, and the pattern was the same in all three
lines: strong in the ventral CNS and eyes and weaker in the
heart and limb mesenchyme. Constancy of expression pat-
tern in independent transgenic lines is the accepted indica-
tion that the expression reflects the intrinsic activity of the
transgene rather than chromosomal position effect. The line
exhibiting the most intense staining, p4:LacZ-17, was used
for further analyses. A heterozygous line was maintained by
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crossing to BALB/c wild-type mice and identifying het-
erozygous transgenic offspring by PCR analysis of tail
DNA.
The transgenic P4 promoter exhibits tissue and stage-
specific activity during embryonic development
To determine whether the P4 promoter was activated
in a stage-specific manner, we analyzed transgenic em-
bryos at eight different developmental stages, including:
3.5 dpc (preimplantation), 7.5 dpc (late gastrulation–
neurulation), 8.5 (neural tube closure, cardiogenesis),
9.5, 10.5, 11.5, 12.5, and 13.5 dpc. Transgenic embryos
were dissected out and stained with X-gal in a whole-
mount format. No staining was observed in 3.5, 7.5, 8.5,
9.5, or 10.5 dpc embryos (Fig. 1A, B data not shown),
indicating that the promoter was inactive during early
development. Weak staining was first observed at 11.5
dpc in the developing CNS, the heart, and visceral em-
bryonic mesoderm (Fig. 1C), indicating tissue-specific
activation of the P4 promoter. By 13.5 dpc, the staining
intensified and also appeared in the limb buds (Fig. 1E).
In comparison, nontransgenic 13.5-dpc embryos showed
only small localized patches of staining (Fig. 1D) due to
endogenous -galactosidase activity. There was no vari-
ation in staining intensity between stained embryos
within a litter, indicating no variation in penetrance.
By 13.5 dpc, the rudiments of all organs have formed.
This stage was chosen, therefore, for a more detailed histo-
logical analysis of sections of the embryos which had been
stained as whole-mounts. The staining pattern observed in
the sections (Fig. 2) indicated cell-type-specific and re-
gional variations in activation of the transgenic P4 pro-
moter.
The CNS exhibited region-specific variation in stain-
ing intensity. In the rostral CNS, staining was stronger in
the ventral areas, including the floorplate of the hindbrain
and anterior spinal cord. In the caudal CNS, on the other
hand, the staining was stronger in the dorsal part of the
neural tube (Fig. 2B, E). Undifferentiated cells of the
germinal layer and differentiated postmitotic neurons of
the mantle layer both stained with approximately equal
intensity (Fig. 2B). Staining was observed in the neural
crest-derived trigeminal and spinal ganglia (Fig. 2B and
data not shown). Weaker staining was also seen in the
retina and lens of the developing eye (Fig. 2B). The nasal
epithelia and the endothelia of some, but not all, blood
vessels stained (Fig. 2C, D, I). Gut epithelium and
surrounding smooth muscle stained. Staining was strong
in cardiomyocytes and heart fibroblasts but absent or
Fig. 1. Transgene expression in middevelopment mouse embryos. Heterozygous transgenic BALB/c animals were mated to BALB/c mice and embryos were
collected on the embryonic days indicated. Embryos were stained in a whole-mount format with the -galactosidase substrate X-gal as described under
Materials and methods and cleared in BABB for photography. (A) 8.5 dpc embryo; (B) 9.5 dpc embryo; (C) 11.5 dpc transgenic embryo; (D) 13.5 dpc
wild-type negative control embryo; (E) 13.5 dpc transgenic embryo.
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extremely weak in hepatocytes (Fig. 2E, F). In the caudal
embryo, where differentiated somites were still present,
staining was observed in the sclerotome (which will
give rise to much of the axial skeleton) and in chondro-
blasts comprising the limb bud cartilage (future site of
bones of the limbs) (Fig. 2E, G, H). The dermatome
(future part of dermis) and the myotome (the most prim-
itive myoblasts) did not not show any P4 activity (Fig.
Fig. 3. Transgene expression in adult organs. Organs dissected from adult transgenic mice were stained in a whole-mount format with the -galactosidase
substrate X-gal as described under Materials and methods and cleared in BABB for photography. (A) Cut face of pontine portion of the brain and posterior
aspect of the cerebellum and enlargement of boxed region showing punctate staining on folia surfaces. (B) Face of coronal slice through the hippocampus
and thalamus of brain and enlargement of boxed region. (C) External aspect of tip of one lobe of the liver and section showing widespread staining in
hepatocytes (largely nuclear localization). (D) Lobe of the adult lung. Dashed line demarks the border of the organ. (E) Cut face of the adult heart and section
showing widespread staining in cardiomyocytes (largely nuclear localization). cb, cerebellum; pn, pons; hc, hippocampus; th, thalamus; pj, Purkinje neurons;
py, pyramidal cell layer; dg, dentate gyrus; br, bronchi.
Fig. 2. Distribution of transgene expression in 13.5 dpc embryonic tissues. 13.5 dpc transgenic embryos were stained in a whole-mount format with the
-galactosidase substrate X-gal, embedded in wax, and sectioned as described under Materials and methods. (A) Transgenic 13.5 dpc embryo stained in
whole-mount format. Labeled lines indicate the level of the sections in the corresponding figure panels. (B) Section through embryonic head at level indicated
in (A). (C) Section through embryonic head at level indicated in (A). (D) Detail of boxed region in (C). (E) Section through thorax and abdomen at level
indicated in (A). (F) Detail of boxed region in (E). (G) Section through tail just posterior to the hind limb bud at the level indicated in (A). (H) Detail of
the boxed region in G. Dashed lines delineate individual somites. The sclerotome and dermomyotome portions of one somite are indicated. (I) Blood vessel
in developing bone primordium counterstained with eosin showing expression in endothelial cells and surrounding chondroblasts. sc, spinal cord; t, trigeminal
ganglia; ml, marginal layer of developing brain; vl, ventricular layer of developing brain; e, eye; D, dorsal aspect of brain and spinal cord; V, ventral aspect
of brain and spinal cord; cp, choroid plexus; ne, nasal epithelium; h, heart; l, liver; b, developing bone; fl, developing forelimb; dmt, dermomyotome portion
of somite; sct, scleratome portion of somite.
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2G, H). Widespread, low-level staining was observed in
mesenchyme.
Tissue-specific activity of the transgenic P4 promoter
continues into adulthood
A tissue-specific pattern of MVM-P4-lacZ expression
was retained in the adult. In the brain, it was expressed in
the Purkinje cells of the cerebellum (Fig. 3A), in the dentate
gyrus and the pyramidal cells of the hippocampus (Fig. 3B),
and in neuronal nuclei in both the dorsal and the ventral
thalamus and the pons (Fig. 3B, data not shown). Staining
was widely distributed in hepatocytes (Fig. 3C). In the
lungs, it was restricted to the epithelia of the larger bronchi
only (Fig. 3D). P4 activitity was retained in adult cardio-
myocytes (Fig. 3E). In the testes, staining was observed in
the cortical portion of the seminiferous tubules coinciding
with the position of the spermatagonia (Fig. 4). More dif-
ferentiated germinal cells, closer to the lumen, did not stain.
Specific staining was observed consistently in the heart,
testicles, and ovaries of transgenic animals. The staining
pattern in the liver, lungs, and brain was consistent, but was
not observed in all transgenic animals examined, suggesting
that the transgene may be subject to an age-dependent
variable silencing in these tissues in the adult, a phenome-
non well described in some transgenic lines (e.g., Cohen-
Tannoudji et al., 2000; Robertson et al., 1996). Staining in
negative control, nontransgenic animals was consistent and
limited (in the tissues examined) to the spleen, the kidney,
and sporadically in the interstitial cells in the testes. There-
fore, we could not determine whether the transgene was also
expressed in these tissues.
Transgenic P4 activity in the testes is restricted to cell
types susceptible to MVM infection
The tissue-specific expression of the P4 transgene, de-
scribed here, suggests that P4 activation may contribute to
MVM tropism. One organ in the adult in which the com-
parison of distribution of infection versus transgene expres-
sion is feasible is the testes, which are experimentally ac-
cessible and express the transgene in mitotic cells. The
testes of sexually mature, 6-week-old transgenic male
BALB/c mice were injected with 3  104 PFU of MVMp
and analyzed 10 days later. The virus was detected with
anti-MVM viral coat protein antibody (Fig. 4B,E). To en-
Fig. 4. Coincidence of transgene expression and productive MVM infection. Section through a testicle of 5-week-old BALB/c transgenic male which had
been injected with infectious MVMp and killed 10 days later. Testicles were stained in whole-mount format for P4 driven -galactosidase activity, sectioned,
and stained for the presence of MVM coat proteins by fluorescent immunohistochemistry using an anti-MVM coat protein primary antibody and a
Cy3-coupled secondary antibody. (A) Dark field image. The birefringent insoluble X-gal cleavage product indicating -galactosidase activity appears bright
pink. (B) Same field as in (A) under fluorescent illumination showing the distribution of Cy3-labeled MVM coat proteins. (C) DAPI counterstaining of same
field showing the distribution of all cell nuclei. (D–E) Higher magnification showing single-cell resolution of top of tubule in (A–C). (D) DIC/dark field
double exposure showing X-gal reaction product (pink). (E) Same field as in (D) under fluorescent illumination showing the distribution of Cy3-labeled MVM
coat proteins. Arrows point to an individual cell showing both -galactosidase activity and MVM coat proteins.
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sure that signal was due to de novo virus production, not the
inoculum, control animals were injected with an equal dose
of UV-irradiated MVMp. The testes were examined in cryo-
sections for cell-specific expression of the transgene and for
the presence of the viral coat antigens.
Transgenic P4 expression (Fig. 4A, D) and viral particles
(Fig. 4B, E) colocalized to the cortical portion of the sem-
iniferous tubules, where the spermatagonia are located. Nei-
ther signal was observed in the more differentiated germinal
cells closer to the lumen. We did not observe any detectable
viral coat protein signal in the more than 100 sections of
testes collected from the animals injected with UV-irradi-
ated MVM, indicating that the immunohistochemical signal
observed was due to de novo virus production, not the
injected virus.
Discussion
The construction of three independent mouse transgenic
lines bearing LacZ reporter sequences under the regulation
of the MVM nonstructural P4 promoter is described here.
Promoter-LacZ transgenes have been shown to faithfully
reproduce the expression patterns of numerous genes (Cui et
al., 1994). However, site-specific variations in the pattern of
expression may result if transgenes come under the influ-
ence of local tissue-specific enhancer/repressor sequences.
The standard approach to preclude studying such an artefact
has been to generate independent transgenic lines and com-
pare their patterns of expression. Despite different chromo-
somal locations, all three of our independent transgenic
lines exhibited the same pattern of P4 promoter activity,
indicating that the transgene expression in the embryo was
due to transgenic sequences, not their chromosomal envi-
ronment.
The tissue distribution of staining clearly showed that the
transgene exhibited stage, tissue, and differentiation-spe-
cific patterns of activity during embryogenesis and in the
adult; the transgenic P4 promoter activity depended upon
both the differentiation state and the cell type. It was silent
during early embryogenesis, at stages containing many
committed and some differentiated cell types. In older em-
bryos, expression in particular cell lineages clearly de-
pended upon the differentiation state. For instance, the early
somites, which will give rise to many mesodermally derived
tissues, did not express the transgene, but by the time the
somite had differentiated into dermatome, myotome, and
sclerotome, the transgenic promoter was active in the scle-
rotome portion only and continued to be active in the bone
primordia of the axial skeleton, which are sclerotome-de-
rived. In the CNS, expression in the undifferentiated neu-
roepithelium did not begin until day 11.5 dpc, 3–4 days
after the formation of this tissue. Expression remained at the
same level in the young postmitotic neurons of the mantle
layer, which are derived from the still mitotic, underlying
neuroepithelium. However, by adulthood, expression was
observed in a very small subset of the differentiated neuro-
nal cell types. In the adult testes, where differentiation status
of the germ line is organized in a gradient from exterior to
interior of the seminiferous tubules, the still mitotic germi-
nal cells—the spermatagonia—activated the P4 promoter,
whereas the more mature, postmeiotic spermatids did not.
Any relevance of the transgene expression pattern to
understanding normal virus–host interactions depends upon
how closely the expression pattern of the integrated P4
promoter reflects its activity in the normal context of the
episomal viral genome. Certainly some viruses having a
distinct tissue or cell-type tropism contain promoter ele-
ments which direct expression to the same cell types in
transgenic animals (Baskar et al., 1996b; Cid et al., 1993;
Honigwachs et al., 1989). The sites of activity of the major
immediate-early promoter (MIEP) of human cytomegalovi-
rus (HCMV) during murine embryogenesis in transgenic
setting correlate with known target tissues of congenital
viral infection in human fetuses (Fritschy et al., 1996; Koe-
dood et al., 1995) and may partially determine the tissue
tropism of the virus in utero (Baskar et al., 1996a). It is
worthwhile noting that the regulatory promoter (P6) of
human parvovirus B19 was sufficient to confer upon a
helper-dependent parvovirus, adenoassociated virus (AAV),
the ability to replicate independently in the B19 normal host
erythroid cells (Wang et al., 1995). In the case of the MVM
P4-reporter transgene described here, the viral promoter
sequence included the entire region upstream of the NS
genes comprising all known promoter elements (Fig. 5)
(Deleu et al., 1998). P4 promoter activity has been studied
in episomal contexts, both viral and plasmid (Ahn et al.,
1989; Christensen et al., 1993; Cornelis et al., 1988; Deleu
et al., 1999; Fuks et al., 1996; Gu et al., 1995; Hanson and
Rhode, 1991; Harris et al., 1999; Perros et al., 1995;
Spegelaere et al., 1991), and in chromosomally integrated
stable transfectants (Deleu et al., 1998). The only observed
context-dependent modulation of P4 activity was shown to
be mediated by NS1 (Hanson and Rhode, 1991). There is,
therefore, reason to think that tissue distribution of the
transgenic promoter activity may be similar to that of the
promoter in the wild-type context.
Further support for this possibility comes from compar-
ing both the temporal and the spatial patterns of activation
of the transgenic promoter with the cell-type host range of
MVM (Table 1). The general timing of embryonic suscep-
tibility to MVM infection matches the timing of transgene
expression. Pregnant mice infected during early gestation
were reported to develop placental infection, while the em-
bryos were unaffected. Infection during mid and late gesta-
tion resulted in intermittent transplacental fetal infection
(Kilham and Margolis, 1970, 1971, 1975; Margolis and
Kilham, 1975). Embryonic stem cells (equivalent to the
inner cell mass cells of the blastocyst, in which we do not
observe transgenic P4 promoter activity) are resistant to
infection. Similarly, mouse embryonal carcinoma cells
(ECC) are resistant to MVM replication, whereas more
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differentiated ECC-derived cell lines are suceptible (Miller
et al., 1977). In our initial studies on embryonic succepti-
bility to MVM infection, we observed infection in embry-
onic spinal ganglia, chondroblasts, and notochord (Table 1)
(Itah et al., unpublished results), tissues which express the
transgene but have not been previously identified as MVM
permissive. In the transgenic mice, the P4 promoter was
inactive until midgestation and was then widely expressed
in the late-gestation embryo. Also, we have not yet identi-
fied embryonic tissues in which the transgene was silent yet
were succeptible to MVM infection. Almost all cell types
known to be susceptible to MVM infection also activated
the transgenic P4 promoter (Table 1). The only exception
was lung capillary endothelium, where infection has been
described, but where we did not observe transgenic P4
activity. We observed viral infection in the spermatagonia-a
mitotically active, easily accessible tissue which also ex-
pressed the transgene. There were cell types which activated
the transgenic P4, but nonetheless are refractive to infection,
for instance, the Purkinje neurons in the brain. This is to be
expected, since host activation of the viral P4 promoter is
necessary, but not sufficient for productive MVM infection.
The comparison of transgenic P4 promoter activity with
MVM infectivity suggests that the integrated genomic con-
text of the transgenic promoter is not drastically altering its
tissue specificity.
Nevertheless, there remains the possibility that promoter
activity is differentially modulated in the viral episomal
context as compared to the chromosomally integrated con-
text. For instance, episomal viral DNA is involved in rep-
lication as well as viral gene expression, and there could be
proteins interacting with the viral terminal hairpin structures
that could alter the tissue specificity of the promoter. For
this reason, the use of a transgenic P4 promoter in this study
must be considered an experimental caveat with respect to
the activity of the same promoter in its viral context. The
levels of expression of transgenic and wild-type promoters
are also almost certainly different. Transgene expression
levels are often affected by transgene copy number, typi-
cally in inverse correlation with the number of tandem
transgenes at the insertion locus (Henikoff, 1998). Most
likely the promoter activity from the one to three copies that
are present in the transgene is less than that observed during
infection. Also, P4 promoter activity during infection is
Fig. 5. The P4-LacZ transgene construct. The SV40 promoter/enhancer of the plasmid pSV--galactosidase (Stratagene) was excised by HindIII and NcoI
cleavage and replaced by a 259 BamHI-NcoI left-end fragment of the MVM genome, containing the P4 promoter and its upstream elements (top). The
promoter elements (Deleu et al., 1998) are indicated: NF-Y, CREB/ATF, USF, E2F, Ets, Sp1, and TBP. Wavy arrow indicates start of transcription.
ATGNS1&2 marks start of coding sequence of NS1 and NS2 proteins. The transgene was excised for injection by cleavage with BamHI (right).
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modulated by its own NS transcription products, which are
absent in the transgenic system.
A tissue-specific regulation of the viral P4 promoter
could be relevant to MVM host range determination. Ac-
cording to current understanding, a cell which is not able to
initiate transcription of the P4 promoter after initial produc-
tion of double-stranded viral DNA should not be able to
sustain a productive MVM infection. Thus, activation of P4
by the host cell is a critical step in the viral life cycle. One
of the most stringent requirements for productive MVM
infection is a mitotic cell population, yet it cannot be argued
that P4 activation is a universal feature of mitotic cells since
the transgenic P4 promoter is silent in the early embryo.
Indeed, the complex pattern of activity of the transgenic
promoter in the context of the almost fully mitotic embryo
raises the possibility that some cells may be refractory to
infection solely because they are incapable of initiating
transcription of the P4 promoter. If so, activation of P4
should be considered one of the host cell-type determinants
of the MVM virus. Although the pattern of transgene ac-
tivity and its correlation with the pattern of MVM infectiv-
ity suggests that this may be so, it is not proven. Further
testing will come from extending the initial correlation
presented here. This research program is currently being
executed in the developing embryo. More definitive data
would also come from observing a change in host cell-type
specificity following infection with MVM bearing a modi-
fied P4 promoter.
Finally, the data suggest that the P4 promoter is worth
considering in attempts to harness the ability of the auton-
omous parvoviruses to preferentially destroy tumors and
transformed cells for therapeutic purposes. The initial ex-
perimental systems to engineer the parvoviruses as potential
cancer therapy vectors have relied upon the activity of the
native P4 promoter (Dupont et al., 2000; Haag et al., 2000;
Kestler et al., 1999; Moehler et al., 2001; Russell et al.,
1992; Telerman et al., 1993). The tissue-type and differen-
tiation state specific activity of the transgenic P4 promoter
described here may provide some indication of the types of
cancers which could be potential targets for this approach.
Materials and methods
Construction of pMVMpP4-LacZ vectors
The MVMp P4-driven LacZ expression vector is shown
in Fig. 5. The SV40 promoter/enhancer sequence in the
vector pSV--galactosidase (Promega) was excised by Hin-
dIII and NcoI cleavage and replaced by blunt-end ligation
with the 259-bp BamHI-NcoI fragment of plasmid
pMM984, which contains the MVMp P4 promoter and its
upstream elements (Merchlinsky et al., 1983). The junction
was verified by sequencing, and -galactosidase activity
was confirmed in transfected NBE (SV40-transformed hu-
man embryo kidney) cells, a cell line in which the P4
promoter is active.
Production of transgenic mice
The P4-LacZ fragment was excised from the plasmid by
BamHI cleavage, DNA purified, and injected into the male
pronuclei of FVB/N fertilized eggs, which were implanted
into pseudopregnant female BALB/c mice. Twenty-eight
offspring were obtained from injected eggs, and three of
these, identified as transgenic by dot blot and Southern blot
analyses of tail DNAs, were chosen for further study. For
dot blot analysis the DNA was left uncut; for Southern
analysis the DNA was cut with BamHI, EcoRV, or HindIII,
electrophoresed on 1% agarose gel, and transferred to ni-
trocellulose. Presence of the transgene was detected by
hybridization with 32P-labeled fragment containing MVM
promoter and -galactosidase sequences. Animals which
tested positive were mated with BALB/c wild-type mice
and the F1 generation mice were similarly analyzed. In
Table 1






Endothelium   a, b
Smooth muscle   b
Mesenchyme/fibroblasts   b
Chondroblast/osteoblast (bone)   e
Undifferentiated germ cells   d
Differentiated germ cells   d
Skeletal muscle   a, b
Hepatocytes   a, b
Cardiomyocytes   a
Lens   e
Epithelium  nd* a
Hematopoietic lineages nd  a, b
Nervous system
Pontine nuclei   c
Dentate gyrus   c
Proliferating neuroepithelium   c
Laterodorsal thalamic nuclei   c
Spinal ganglia   e
Pyramidal cells   c
Purkinje cells   c
External granular layer cells nd † b
Note. Tropism of MVM for murine host cells and the tissue distribution
of the P4-LacZ transgene activity are listed by tissue type. Data from
different age host animals, different viral strains, and different murine host
strains are pooled. Viral strains and references are listed on the right. ()
Positive for either infection or expression. () Negative for infection or
expression. (nd) Not determined. References are (a) Brownstein et al.
(1991); (b) Brownstein et al. (1992); (c) Ramirez et al. (1996); (d) results
of this study; (e) Itah et al. (unpublished data).
* Although not described as a target tissue in the literature, the fact that
oronasal application of MVM is a typical experimental infection route
suggests that epithelium may become infected.
† Infection has been described in the external granular layer and in the
granular neurons of the cerebellum, which migrate from the still mitotic
external granular layer. Since the granular neurons are postmitotic, it was
proposed that the signal observed in these was due to infection prior to
migration (Ramirez et al., 1996).
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further generations, transgenic animals were identified by
PCR of tail DNA using the primers 5-GCGAAAAG-
GAAGTGGGCGTGGT-3 (nt 147–168 within the MVM
sequence) and 5-GGGATCGATCTCGCCATACAGCG-3
(nt 210–477 within the -galactosidase open reading
frame), which amplifies a ca. 500-bp transgene-specific
fragment.
Whole-mount analysis of -galactosidase expression
The morning when a plug was observed was considered
to be 0.5 dpc. Embryos were collected at 3.5 (blastocysts),
7.5 (late gastrulation), 8.5, 9.5, 10.5, 11.5, 12.5, and 13.5
dpc and then were fixed intact in 4% paraformaldehyde in
PBS for no more than 40 min at room temperature. Older
embryos and adult organs were bisected after 10 min and
then fixed for an additional 30 min. Staining with the -ga-
lactosidase substrate X-gal was done according to a stan-
dard procedure (Bonnerot and Nicolas, 1993). Embryos
were stained for 20 to 36 h at 30°C. Samples were cleared
by dehydration through an ethanol series followed by incu-
bation in a mixture of benzyl alcohol:benzyl benzoate (1:2).
Histology
Stained 13.5-dpc heterozygous transgenic embryos were
dehydrated through an ethanol series into xylene and em-
bedded in paraffin wax. Serial sections cut at 25 m were
collected, dewaxed, and mounted in permount.
Viral infections
Sexually mature, 6-week-old transgenic males were
anesthetized with Metofane to effect. CsCl-purified MVMp
stock virus, titered by plaque assay on NB324K cells (Tat-
tersall and Bratton, 1983), was diluted to 1000 PFU/l.
Thirty microliters was injected into each testicle. Negative
control mice were injected with the same dose of UV-
inactivated MVM. Mice were sacrificed 10 days after injec-
tion and their testes analyzed.
Combined immunohistochemistry and -galactosidase
staining
The injected testes were first stained for -galactosidase
activity in the whole-mount format as above. They were
then frozen in OCT and cryosections collected for immu-
nohistochemistry. Viral capsid proteins were identified by
immunohistochemistry using a rabbit polyclonal antiserum
against the MVM-coat proteins and a Cy3-labeled anti-
serum against rabbit IgG. Localization of lacZ and viral coat
proteins in the same sample was accomplished by photog-
raphy first under dark field illumination to detect the X-gal
staining product. The same field of view was then photo-
graphed under epifluorescence to identify the viral coat
proteins. Sections were counterstained with DAPI for visu-
alization of all cell nuclei.
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